Renfu Pharmaceutical (600079.SH): Midazolam injection approved for marketing in Germany

Zhitongcaijing · 3d ago

Zhitong Finance App News, Renfu Pharmaceutical (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”), received a marketing license approval letter for midazolam injections approved and issued by the German Federal Administration for Drugs and Medical Devices (BfArM).

According to the announcement, midazolam injections have obtained marketing approval from the German Federal Agency for Drugs and Medical Devices (BfArM). The approved indications include: 1) sober sedation before, after and during diagnostic or therapeutic procedures (whether combined with local anesthesia or not); 2) preoperative use before induction of anesthesia in adults, anesthesia induction, and use in combination with other anesthetics as sedatives; preoperative use before induction of anesthesia in children; 3) sedation in intensive care units (ICU).